RXi Pharmaceuticals appoints new director to board

WORCESTER, Mass. A biopharmaceutical company that develops drugs based on RNA interference has made a new appointment to its board of directors.

RXi Pharmaceuticals Corp. announced the appointment of Richard Chin to its board of directors, effective April 23.

Chin is currently CEO of the nonprofit drug maker Institute for OneWorld Health, which develops drugs for neglected diseases in developing countries. Chin joined OneWorld Health from OXiGENE, which develops vascular-targeting drugs for cancer and ophthalmology, where he served as president and CEO. He has also worked for Elan Corp., Genentech and Procter & Gamble Pharmaceuticals.

“I am honored to be part of this exciting, growing company that is working to create some truly innovative new therapeutics,” Chin stated.